To our knowledge, no prospective clinical data has yet been published on the combination of radiation and ICIs in patients with oligometastatic HNSCC, though there is at least one ongoing clinical trial (NCT03283605, which examines the use of durvalumab, tremelimumab [a CTLA-4 inhibitor], and SBRT in patients with HNSCC with fewer than 10 metastases). This evidence concerns the gene CTLA4 and head and neck squamous cell carcinoma.